Systemic NPR1 antagonism intended to improve central blood volume in POTS may paradoxically worsen exercise intolerance and increase long-term metabolic risk.
Systemic NPR1 inhibition for POTS requires careful evaluation of metabolic and functional endpoints, as reducing natriuretic peptide signaling may inadvertently compromise skeletal muscle energetics and exercise capacity.
Jordan et al. (Tue,) conducted a letter in Postural orthostatic tachycardia syndrome (POTS). NPR1 antagonist (REGN7544) was evaluated. Systemic NPR1 antagonism intended to improve central blood volume in POTS may paradoxically worsen exercise intolerance and increase long-term metabolic risk.